Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Executive Summary
Roche/GlaxoSmithKline's aggressive pricing strategy for Boniva injection relative to the oral formulation indicates the firms feel Medicare Part B is a more advantageous reimbursement environment than Part D
You may also be interested in...
End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP
Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward
Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said
Boniva I.V. Once-Quarterly Safety Concerns Few, But Renal Tests Advised
Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests